EVM
CORT icon

Eaton Vance Management’s Corcept Therapeutics CORT Stock Holding History

Eaton Vance Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$2.56M Sell
100,000
-165
-0.2% -$4.42K ﹤0.01% 977
2022
Q2 		$2.38M Sell
100,165
-2,464
-2% -$53.7K ﹤0.01% 1024
2022
Q1 		$2.31M Buy
102,629
+1,141
+1% +$24.3K ﹤0.01% 1130
2021
Q4 		$2.01M Buy
101,488
+226
+0.2% +$4.58K ﹤0.01% 1024
2021
Q3 		$1.97M Sell
101,262
-112
-0.1% -$2.34K ﹤0.01% 939
2021
Q2 		$2.23M Buy
101,374
+562
+0.6% +$12.5K ﹤0.01% 985
2021
Q1 		$2.4M Buy
100,812
+382
+0.4% +$10.2K ﹤0.01% 933
2020
Q4 		$2.63M Buy
100,430
+8
+0% +$169 ﹤0.01% 868
2020
Q3 		$1.75M Sell
100,422
-28
-0% -$446 ﹤0.01% 866
2020
Q2 		$1.69M Buy
100,450
+72
+0.1% +$1.01K ﹤0.01% 850
2020
Q1 		$1.19M Buy
100,378
+19
+0% +$235 ﹤0.01% 867
2019
Q4 		$1.21M Sell
100,359
-5
-0% -$70 ﹤0.01% 935
2019
Q3 		$1.42M Buy
100,364
+107
+0.1% +$1.31K ﹤0.01% 881
2019
Q2 		$1.12M Buy
+100,257
New +$1.12M ﹤0.01% 922

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eaton Vance Management's CORT Position: Q3 2022 in Review

Eaton Vance Management reduced its Corcept Therapeutics (CORT) stake by 0.16% in Q3 2022, selling an estimated $4.42K and leaving 100,000 shares worth $2.56M. The position accounts for ﹤0.01% of the portfolio, ranked #977.

Eaton Vance Management first reported a position in CORT in Q2 2019 and has held it in 14 quarters since. The position peaked at $2.63M in Q4 2020. 239 funds tracked by Wall St. Rank hold CORT as of Q3 2022.

  • Eaton Vance Management held 100,000 shares of Corcept Therapeutics worth $2.56M as of Q3 2022.
  • Eaton Vance Management sold 165 Corcept Therapeutics shares in Q3 2022, an estimated $4.42K.
  • Corcept Therapeutics made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #977 holding.
  • Eaton Vance Management first reported a position in Corcept Therapeutics in Q2 2019 and has held it in 14 quarters since.
  • Eaton Vance Management's Corcept Therapeutics position peaked at $2.63M in Q4 2020.
  • 239 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.